These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
32. Disease-modifying effects of edasalonexent, an NF-κB inhibitor, in young boys with Duchenne muscular dystrophy: Results of the MoveDMD phase 2 and open label extension trial. Finkel RS; Finanger E; Vandenborne K; Sweeney HL; Tennekoon G; Shieh PB; Willcocks R; Walter G; Rooney WD; Forbes SC; Triplett WT; Yum SW; Mancini M; MacDougall J; Fretzen A; Bista P; Nichols A; Donovan JM Neuromuscul Disord; 2021 May; 31(5):385-396. PubMed ID: 33678513 [TBL] [Abstract][Full Text] [Related]
33. High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy. Connolly AM; Schierbecker J; Renna R; Florence J Neuromuscul Disord; 2002 Dec; 12(10):917-25. PubMed ID: 12467746 [TBL] [Abstract][Full Text] [Related]
34. Recombinant human insulin-like growth factor-1 therapy for 6 months improves growth but not motor function in boys with Duchenne muscular dystrophy. Rutter MM; Wong BL; Collins JJ; Sawnani H; Taylor MD; Horn PS; Backeljauw PF Muscle Nerve; 2020 May; 61(5):623-631. PubMed ID: 32108355 [TBL] [Abstract][Full Text] [Related]
35. Corticosteroids in Duchenne muscular dystrophy: a reappraisal. Wong BL; Christopher C J Child Neurol; 2002 Mar; 17(3):183-90. PubMed ID: 12026233 [TBL] [Abstract][Full Text] [Related]
36. Steroid treatment and the development of scoliosis in males with duchenne muscular dystrophy. Alman BA; Raza SN; Biggar WD J Bone Joint Surg Am; 2004 Mar; 86(3):519-24. PubMed ID: 14996877 [TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics and safety of single doses of drisapersen in non-ambulant subjects with Duchenne muscular dystrophy: results of a double-blind randomized clinical trial. Flanigan KM; Voit T; Rosales XQ; Servais L; Kraus JE; Wardell C; Morgan A; Dorricott S; Nakielny J; Quarcoo N; Liefaard L; Drury T; Campion G; Wright P Neuromuscul Disord; 2014 Jan; 24(1):16-24. PubMed ID: 24321374 [TBL] [Abstract][Full Text] [Related]
38. Mechanisms and Clinical Applications of Glucocorticoid Steroids in Muscular Dystrophy. Quattrocelli M; Zelikovich AS; Salamone IM; Fischer JA; McNally EM J Neuromuscul Dis; 2021; 8(1):39-52. PubMed ID: 33104035 [TBL] [Abstract][Full Text] [Related]
39. Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial. Nagy S; Hafner P; Schmidt S; Rubino-Nacht D; Schädelin S; Bieri O; Fischer D Trials; 2019 Nov; 20(1):637. PubMed ID: 31752977 [TBL] [Abstract][Full Text] [Related]
40. An Open Label Exploratory Clinical Trial Evaluating Safety and Tolerability of Once-Weekly Prednisone in Becker and Limb-Girdle Muscular Dystrophy. Zelikovich AS; Joslin BC; Casey P; McNally EM; Ajroud-Driss S J Neuromuscul Dis; 2022; 9(2):275-287. PubMed ID: 35124660 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]